Early lung cancer with lepidic pattern: Adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 4, 2014, Pages 309-316

  Weichert, Wilko ^a   Warth, Arne ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

adenocarcinoma in situ; computed tomography; histology; lepidic; minimally invasive adenocarcinoma

Indexed keywords

ADENOCARCINOMA IN SITU; ADENOMA; ATYPICAL ADENOMATOUS HYPERPLASIA; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EARLY CANCER; LEPIDIC PATTERN; LEPIDIC PREDOMINANT ADENOCARCINOMA; LUNG ADENOCARCINOMA; MINIMALLY INVASIVE ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; ADENOCARCINOMA; DECISION MAKING; HUMAN; LUNG TUMOR; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; DECISION MAKING; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901844946     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000065     Document Type: Review

References (64)

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244-285.
2. Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 2013; 147:921-928.
3. Gu J, Lu C, Guo J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 2013; 107:474-480.
4. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013; 258:1079-1086.
5. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012; 25:1117-1127.
6. Kadota K, Yeh YC, Sima CS, et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 2013. [Epub ahead of print]
7. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisci-plinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-1504.
8. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarci-nomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010; 34:1155-1162.
9. Song Z, Zhu H, Guo Z, et al. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients-based on a hospital study in China. Eur J Surg Oncol 2013; 39:1262-1268.
10. Sterlacci W, Savic S, Schmid T, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 2012; 137:946-956.
11. Takahashi M, Shigematsu Y, Ohta M, et al. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. J Thorac Cardiovasc Surg 2014; 147:54-59.
12. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012; 30:1438-1446.
13. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24:653-664.
14. Zhang J, Wu J, Tan Q, et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 2013; 8:1196-1202.
15. Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopatho-logical subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012; 25:1574-1583.
16. Warth A, Cortis J, Fink L, et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012; 461:185-193.
17. Warth A, Stenzinger A, von Brunneck AC, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary ade-nocarcinomas. Eur Respir J 2012; 40:1221-1227.
18. Sakurai H, Asamura H, Miyaoka E, et al. Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype: a retrospective analysis of Japanese lung cancer registry data. Eur J Cardi-othorac Surg 2014; 45:100-107.
19. Campos-Parra AD, Aviles A, Contreras-Reyes S, et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J 2014. [Epub ahead of print]
20. Weissferdt A, Kalhor N, Marom EM, et al. Early-stage pulmonary adenocarci-noma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. Mod Pathol 2013; 26:1065-1075.
21. Jones KD. Whence lepidic?: the history of a Canadian neologism. Arch Pathol Lab Med 2013; 137:1822-1824.
22. Ahn S, Hwangbo W, Kim H, Kim CH. Naked cuticle Drosophila 1expression in histologic subtypes of small adenocarcinoma of the lung. Korean J Pathol 2013; 47:211-218.
23. Woo T, Okudela K, Mitsui H, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int 2012; 62:785-791.
24. Yanagawa N, Shiono S, Abiko M, et al. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 2013; 8:612-618.
25. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8:52-61.
26. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and non-mucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014. [Epub ahead of print]
27. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013; 81:371-376.
28. Xu L, Tavora F, Battafarano R, Burke A. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society. Am J Surg Pathol 2012; 36:273-282.
29. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75:2844-2852.
30. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28:198-206.
31. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000; 69:893-897.
32. Doxtader EE, Mukhopadhyay S, Katzenstein AL. Biopsy-site changes in lung adenocarcinoma with prior core needle biopsy: a potential pitfall in the assessment of stromal invasion. Am J Surg Pathol 2013; 37:443-446.
33. Yeh YC, Wu YC, Chen CY, et al. Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: his-topathological categories for prognosis prediction. J Clin Pathol 2012; 65:910-918.
34. Walts AE, Marchevsky AM. Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung. Arch Pathol Lab Med 2012; 136:1515-1521.
35. Gu B, Burt BM, Merritt RE, et al. A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease. Ann Thorac Surg 2013; 96:411-418.
36. Kim HK, Choi YS, Kim J, et al. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol 2010; 5:206-210.
37. Mun M, Kohno T. Efficacy of thoracoscopic resection for multifocal bronch-ioloalveolar carcinoma showing pure ground-glass opacities of 20mm or less in diameter. J Thorac Cardiovasc Surg 2007; 134:877-882.
38. Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg 2004; 78:1194-1199.
39. Tsutsui S, Ashizawa K, Minami K, et al. Multiple focal pure ground-glass opacities on high-resolution CT images: clinical significance in patients with lung cancer. AJR Am J Roentgenol 2010; 195:W131-138.
40. Tsutani Y, Miyata Y, Mimae T, et al. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg 2013; 146:580-585.
41. Zhang Y, Sun Y, Shen L, et al. Predictive factors of lymph node status in small peripheral nonsmall cell lung cancers: tumor histology is more reliable. Ann Surg Oncol 2013; 20:1949-1954.
42. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009; 33:462-469.
43. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31:992-1001.
44. Thunnissen E, Belien JA, Kerr KM, et al. In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarci-noma. Arch Pathol Lab Med 2013; 137:1792-1797.
45. Honda T, Kondo T, Murakami S, et al. Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification. Clin Radiol 2013; 68:e21-e26.
46. Lederlin M, Puderbach M, Muley T, et al. Correlation of radio-and histomor-phological pattern of pulmonary adenocarcinoma. Eur Respir J 2013; 41:943-951.
47. Sawabata N, Kanzaki R, Sakamoto T, et al. Clinical predictor of pre or minimally invasive pulmonary adenocarcinoma: possibility of sub-classification of clinical T1a. Eur J Cardiothorac Surg 2014; 45:256-261.
48. Ambrosini-Spaltro A, Ruiu A, Seebacher C, et al. Impact of the IASLC/ATS/ERS classification in pN0 pulmonary adenocarcinomas: a study with radiological-pathological comparisons and survival analyses. Pathol Res Pract 2014; 210:40-46.
49. Cho S, Song IH, Yang HC, et al. Predictive factors for node metastasis in patients with clinical stage I nonsmall cell lung cancer. Ann Thorac Surg 2013; 96:239-245.
50. Jiang B, Takashima S, Hakucho T, et al. Adenocarcinoma of the lung with scattered consolidation: radiological-pathological correlation and prognosis. Eur J Radiol 2013; 82:e623-e627.
51. Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J Cardiothorac Surg 2013; 43:915-918.
52. Murakawa T, Konoeda C, Ito T, et al. The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma. Eur J Cardiothorac Surg 2013; 43:925-932.
53. Tsutani Y, Miyata Y, Yamanaka T, et al. Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings. J Thorac Cardiovasc Surg 2013; 146: 17-23.
54. Lim HJ, Ahn S, Lee KS, et al. Persistent pure ground-glass opacity lung nodules > 10mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest 2013; 144:1291-1299.
55. Ichinose J, Kohno T, Fujimori S, et al. Invasiveness and malignant potential of pulmonary lesions presenting as pure ground-glass opacities. Ann Thorac Cardiovasc Surg 2013. [Epub ahead of print]
56. Lee HY, Jeong JY, Lee KS, et al. Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: prognostic stratification with functional and metabolic imaging biomarkers. J Magn Reson Imaging 2013; 38:905-913.
57. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361:2221-2229.
58. Van Schil PE, Asamura H, Rusch VW, et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J 2012; 39: 478-486.
59. Onozato ML, Kovach AE, Yeap BY, et al. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol 2013; 37:287-294.
60. Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011; 135:1329-1334.
61. Song Z, Zhu H, Guo Z, et al. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 2013; 30:645.
62. Warth A, Penzel R, Lindenmaier H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 2013; 43:872-883.
63. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-326.
64. Hata A, Katakami N, Fujita S, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 2010; 5:1197-1200.